Evidence map›Paper›PMID 39881056›Full record

ArticlePharmacological reports : PR2025

Olaparib-induced hyperglycemia in ovarian cancer patients - a case series analysis of a three-month therapy with a consideration of BMI.

Joanna Stanisławiak-Rudowicz, Edyta Szałek, Barbara Więckowska, Edmund Grześkowiak, Radosław Mądry

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmacological reports : PR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Joanna Stanisławiak-RudowiczDepartment of Clinical Pharmacy and Biopharmacy, Poznań University of Medical Sciences, Rokietnicka 3, Poznań, Poland. stanisl@interia.pl.
Edyta SzałekDepartment of Clinical Pharmacy and Biopharmacy, Poznań University of Medical Sciences, Rokietnicka 3, Poznań, Poland.
Barbara WięckowskaDepartment of Computer Science and Statistics, Poznań University of Medical Sciences, Poznań, Poland.
Edmund GrześkowiakDepartment of Clinical Pharmacy and Biopharmacy, Poznań University of Medical Sciences, Rokietnicka 3, Poznań, Poland.
Radosław MądryDepartment of Gynaecological Oncology, Poznań University Clinical Hospital, Szamarzewskiego 84, Poznań, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOlaparib is a relatively new poly(ADP-ribose) polymerase inhibitor (PARPi) administered to ovarian cancer (OC) patients with a complete or partial response to first-line chemotherapy. One of the metabolic side effects of olaparib is the disruption of glucose homeostasis, often resulting in hyperglycemia The study was a retrospective analysis of olaparib-induced hyperglycemia in OC patients with initial normoglycemia following the first, second, and third month of olaparib treatment

methodsThe study involved 32 OC patients, classified into three groups according to their Body Mass Index (BMI): normal BMI (BMI 18.5-24.9 kg/m

resultsA significant increase in glycemia was observed after the first and second cycles of olaparib treatment in the group with normal BMI and after the third cycle in overweight and obese patients. There were no significant differences in glucose levels among the groups following the first, the second, and the third cycle. Grade 1 hyperglycemia with impaired fasting glucose levels (5.6-6.9 mmol/l) was found in 15 patients (normal BMI: n = 4, overweight: n = 9, and obesity: n = 2), while glycemia typical of diabetes (≥ 7.0 mmol/l) was observed in one obese patient.

conclusionsRegardless of the weight of OC patients, it is essential to control glycemia during olaparib treatment.

Indexed as

Antineoplastic AgentsHyperglycemiaOvarian NeoplasmsPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsAdultAgedBlood GlucoseBody Mass IndexFemaleHumansMiddle AgedObesityOverweightRetrospective StudiesAntineoplastic AgentsBlood GlucoseolaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsAdverse effectsBMIHyperglycemiaOlaparib

Identifiers

PMID39881056

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.